• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

风险因素是分析、解释和理解事件发生时间数据的关键量。

Hazards Constitute Key Quantities for Analyzing, Interpreting and Understanding Time-to-Event Data.

作者信息

Beyersmann Jan, Schmoor Claudia, Schumacher Martin

机构信息

Institute of Statistics, Ulm University, Ulm, Germany.

Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.

出版信息

Biom J. 2025 Jun;67(3):e70057. doi: 10.1002/bimj.70057.

DOI:10.1002/bimj.70057
PMID:40474657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12142306/
Abstract

Censoring makes time-to-event data special and requires customized statistical techniques. Survival and event history analysis therefore builds on hazards as the identifiable quantities in the presence of rather general censoring schemes. The reason is that hazards are conditional quantities, given previous survival, which enables estimation based on the current risk set-those still alive and under observation. But it is precisely their conditional nature that has made hazards subject of critique from a causal perspective: A beneficial treatment will help patients survive longer than had they remained untreated. Hence, in a randomized trial, randomization is broken in later risk sets, which, however, are the basis for statistical inference. We survey this dilemma-after all, mapping analyses of hazards onto probabilities in randomized trials is viewed as still having a causal interpretation-and argue that a causal interpretation is possible taking a functional point of view. We illustrate matters with examples from benefit-risk assessment: Prolonged survival may lead to more adverse events, but this need not imply a worse safety profile of the novel treatment. These examples illustrate that the situation at hand is conveniently parameterized using hazards, that the need to use survival techniques is not always fully appreciated and that censoring not necessarily leads to the question of "what, if no censoring?" The discussion should concentrate on how to correctly interpret causal hazard contrasts and analyses of hazards should routinely be translated onto probabilities.

摘要

删失使事件发生时间数据具有特殊性,需要采用定制的统计技术。因此,生存分析和事件史分析基于风险构建,因为在相当一般的删失方案下,风险是可识别的量。原因在于,风险是给定先前生存情况的条件量,这使得能够基于当前风险集(仍存活且处于观察中的个体)进行估计。但正是它们的条件性质使得风险从因果角度受到批评:一种有益的治疗方法会帮助患者比未接受治疗存活更长时间。因此,在随机试验中,随机化在后续风险集中被打破,然而,这些风险集是统计推断的基础。我们审视了这一困境——毕竟,在随机试验中将风险分析映射到概率上仍被视为具有因果解释——并认为从功能角度来看,因果解释是可能的。我们用效益 - 风险评估的例子来说明这些问题:延长的生存期可能会导致更多不良事件,但这不一定意味着新治疗方法的安全性更差。这些例子表明,使用风险可以方便地对当前情况进行参数化,使用生存技术的必要性并不总是被充分理解,而且删失不一定会引发“如果没有删失会怎样?”这样的问题。讨论应集中在如何正确解释因果风险对比,并且风险分析应常规地转化为概率分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c2/12142306/9530c841ea08/BIMJ-67-e70057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c2/12142306/069037520eb7/BIMJ-67-e70057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c2/12142306/9530c841ea08/BIMJ-67-e70057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c2/12142306/069037520eb7/BIMJ-67-e70057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24c2/12142306/9530c841ea08/BIMJ-67-e70057-g002.jpg

相似文献

1
Hazards Constitute Key Quantities for Analyzing, Interpreting and Understanding Time-to-Event Data.风险因素是分析、解释和理解事件发生时间数据的关键量。
Biom J. 2025 Jun;67(3):e70057. doi: 10.1002/bimj.70057.
2
Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.左截断和右删失情况下特定病因累积发病率估计及精细灰色模型
Biometrics. 2011 Mar;67(1):39-49. doi: 10.1111/j.1541-0420.2010.01420.x.
3
Consistent estimation of the expected Brier score in general survival models with right-censored event times.在具有右删失事件时间的一般生存模型中对预期Brier评分进行一致估计。
Biom J. 2006 Dec;48(6):1029-40. doi: 10.1002/bimj.200610301.
4
Causal interpretation of the hazard ratio in randomized clinical trials.随机临床试验中风险比的因果解释。
Clin Trials. 2024 Oct;21(5):623-635. doi: 10.1177/17407745241243308. Epub 2024 Apr 28.
5
Double inverse-weighted estimation of cumulative treatment effects under nonproportional hazards and dependent censoring.非比例风险和相依删失下累积治疗效果的双重逆加权估计
Biometrics. 2011 Mar;67(1):29-38. doi: 10.1111/j.1541-0420.2010.01449.x.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Fundamentals of survival data.生存数据基础
Biometrics. 1999 Mar;55(1):13-22. doi: 10.1111/j.0006-341x.1999.00013.x.
8
Estimation of treatment effect under non-proportional hazards and conditionally independent censoring.在非比例风险和条件独立删失下的治疗效果估计。
Stat Med. 2012 Dec 10;31(28):3504-15. doi: 10.1002/sim.5440. Epub 2012 Jul 4.
9
Estimation of integrated transition hazards and stage occupation probabilities for non-Markov systems under dependent censoring.相依删失下非马尔可夫系统的累积转移风险和阶段占据概率估计
Biometrics. 2002 Dec;58(4):792-802. doi: 10.1111/j.0006-341x.2002.00792.x.
10
The importance of censoring in competing risks analysis of the subdistribution hazard.在亚分布风险的竞争风险分析中删失的重要性。
BMC Med Res Methodol. 2017 Apr 4;17(1):52. doi: 10.1186/s12874-017-0327-3.

本文引用的文献

1
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines.AdVerse 事件的生存分析,随访时间可变(SAVVY):研究结果总结和现有指南评估。
Trials. 2024 May 31;25(1):353. doi: 10.1186/s13063-024-08186-7.
2
Considering Questions Before Methods in Dementia Research With Competing Events and Causal Goals.考虑存在竞争事件和因果目标的痴呆症研究中的方法前问题。
Am J Epidemiol. 2023 Aug 4;192(8):1415-1423. doi: 10.1093/aje/kwad090.
3
A connection between survival multistate models and causal inference for external treatment interruptions.
生存多状态模型与外部治疗中断因果推断的联系。
Stat Methods Med Res. 2023 Feb;32(2):267-286. doi: 10.1177/09622802221133551. Epub 2022 Dec 4.
4
Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.肿瘤学临床试验中事件时间终点分析的统计学考虑:以 CAR-T 免疫疗法研究为例。
Clin Cancer Res. 2022 Sep 15;28(18):3940-3949. doi: 10.1158/1078-0432.CCR-22-0560.
5
General independent censoring in event-driven trials with staggered entry.具有交错入组的事件驱动试验中的一般独立censoring。
Biometrics. 2023 Sep;79(3):1737-1748. doi: 10.1111/biom.13710. Epub 2022 Jul 19.
6
Translating questions to estimands in randomized clinical trials with intercurrent events.在伴有中间事件的随机临床试验中,将问题转化为评估目标。
Stat Med. 2022 Jul 20;41(16):3211-3228. doi: 10.1002/sim.9398. Epub 2022 May 16.
7
Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.标志着临床试验新思维的 2 年:效应量估计之旅。
Ther Innov Regul Sci. 2022 Jul;56(4):637-650. doi: 10.1007/s43441-022-00402-3. Epub 2022 Apr 24.
8
Bivariate pseudo-observations for recurrent event analysis with terminal events.用于带有终末事件的复发事件分析的双变量伪观测值。
Lifetime Data Anal. 2023 Apr;29(2):256-287. doi: 10.1007/s10985-021-09533-5. Epub 2021 Nov 5.
9
Methodological challenges in the analysis of recurrent events for randomised controlled trials with application to cardiovascular events in LEADER.随机对照试验中复发事件分析的方法学挑战及其在LEADER研究心血管事件中的应用
Pharm Stat. 2022 Jan;21(1):241-267. doi: 10.1002/pst.2167. Epub 2021 Sep 7.
10
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.不同随访时间的不良事件生存分析(SAVVY)-不良事件风险估计
Trials. 2021 Jun 29;22(1):420. doi: 10.1186/s13063-021-05354-x.